Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
The Indian companies battling drug-resistant superbugs
Indian biotech start-up Bugworks, supported by CARB-X, aims to develop new antibiotics against superbugs amidst India's severe drug-resistance crisis. Despite financial hurdles, India's government and companies are pushing for solutions, with Bugworks and others nearing clinical trials. India's large patient base and pharmaceutical industry position it as a key player in combating antimicrobial resistance globally.
Neurotrophic Keratitis Market | Global Analysis Report 2027
The article provides a comprehensive analysis of the global neurotrophic keratitis market, including market segmentation, treatment types (drugs and surgical interventions), stages, and regional forecasts from 2017 to 2027. It highlights key industry developments, pipeline analysis, and competitive landscape, featuring major companies like Dompe farmaceutici S.p.A., Allergan, and others.
Prucalopride in the treatment of chronic constipation
Prucalopride 2 mg significantly improved bowel function in chronic constipation patients from the Asia-Pacific region over 12 weeks, with 33.3% achieving ≥3 spontaneous complete bowel movements per week vs 10.3% on placebo (P < 0.001). It was safe, well-tolerated, with common adverse events being diarrhea, nausea, abdominal pain, and headache.
Xarelto okayed by FDA for treating atrial fibrillation
The FDA approved Xarelto, a next-gen blood thinner, for atrial fibrillation treatment, offering an alternative to warfarin. Xarelto, effective once daily, blocks clotting protein factor Xa, similar in stroke prevention to warfarin but with a boxed warning against abrupt discontinuation due to stroke risk.
CAR-T Cell Therapy Market - Market Size, Forecasts, Trials
CAR-T cell therapy, a groundbreaking immunotherapy, modifies patient T-cells to target and destroy cancer cells, acting as 'living drugs.' With 11 products commercialized, including 7 FDA-approved, the therapy shows promise in treating blood cancers. Challenges include expanding to solid tumors, reducing 'vein-to-vein' time, and improving reimbursement. The industry is advancing through gene-transfer techniques, partnerships, and 'on-off' switches in CAR-T cells to enhance efficacy and safety.
© Copyright 2025. All Rights Reserved by MedPath